Document is current
Any future updates will be listed below
-
Authors
Busque, Lambert https://orcid.org/0000-0002-5375-3749
Beaudet, Marc-Étienne
Harnois, Michaël
Moussa, Hanane
Szuber, Natasha https://orcid.org/0000-0003-1499-6171
Mollica, Luigina
Delage, Robert
Olney, Harold
Laneuville, Pierre
Cournoyer, Ghislain
Chamakhi, Inès
Lalancette, Marc
Talbot, Danielle
Ethier, Vincent
Desjardins, Pierre
Assouline, Sarit https://orcid.org/0000-0002-7638-1589
- License Information
-
More Information
Article History
Received: 11 November 2024
Revised: 20 January 2025
Accepted: 20 February 2025
First Online: 11 March 2025
Competing interests
: LB, GC, RD, ML, and VE participated in advisory boards for Novartis. LM, M-EB, DT, and IC have nothing to declare. NS is a clinician scientist of the FRQS.
: The study protocol was conducted in accordance with the principles of the Declaration of Helsinki (as revised in 2013) and approved by the Institutional Review Board (IRB) of all participating centers. The approbation is renewed every year with CÉR CIUSSS-EIMTL (ethics committee).
: All patients signed an informed consent.
